The arthritis and ulcerative colitis drug Xeljanz (tofacitinib) could potentially increase the risk of heart-related problems and cancer, according to a February 2021 U.S. Food and Drug Administration Drug Safety Communication. “The U.S. Food and Drug Administration (FDA) is alerting the public that preliminary results…
An analysis published in the Journal of the American Medical Association (JAMA) Network Open, suggests Zantac and drugs containing ranitidine may cause high…
Drugwatch.com is excited to announce the addition of three respected health care professionals to our network of expert contributors. Along with Drugwatch’s other…
Drugwatch’s senior writer Michelle Llamas has joined the National Center for Health Research’s PCORI COVID-19 Press Teleconference Advisory Board. The…
Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.
Drugwatch's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.
